99% Growth-Hormone Bodybuilding Peptide Tesamorelin for Muscle Growing 218949-48-5

Quick Detail:

Product Name: Tesamorelin

Other Name: usan; Egrifta

CAS: 218949-48-5

MF: C211H366N72O67S1

MW: 5135.89

Appearance: white powder

Purity (HPLC): 99.3%

Molecular Weight:5135.89

Appearance:white powder

Packing :According to every customer's requirement.

Catrgory :Polypeptides Hormone

Tesamorelin Description:
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group.
Tesamorelin ( also known as Egrifta) is a synthetic form of growth-hormone-releasing hormone which is used in the treatment of HIV-associated lipodystrophy.
p; tendon fibroblasts in a dose-dependent manner as revealed by transwell filter migration assay. BPC 157 also dose dependently accelerated the spreading of tendon fibroblasts on culture dishes. The F-actin formation as detected by FITC-phalloidin staining was induced in BPC 157-treated fibroblasts. The protein expression and activation of FAK and paxillin were determined by Western blot analysis, and the phosphorylation levels of both FAK and paxillin were dose dependently increased by BPC 157 while the total amounts of protein was unaltered. In conclusion, BPC 157 promotes the ex vivo outgrowth of tendon fibroblasts from tendon explants, cell survival under stress, and the in vitro migration of tendon fibroblasts, which is likely mediated by the activation of the FAK-paxillin pathway.

Function:

GHRF causes growth hormone to be created and spread in the body, which helps increase metabolism, reduce belly fat, improve body shape, and use of energy. Tesamorelin (formerly known as TH9507) is a synthetic growth hormone-releasing factor that stimulates the pituitary gland in the brain to secrete growth hormone; this indirect approach appears to maintain more stable, natural levels, like CJC-1295 DAC.Clinical trials have shown that tesamorelin significantly reduces abdominal fat with fewer side effects than human growth hormone itself, although abdominal fat may return after the Tesamorlein is discontinued (depending upon the individual). Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals as well as similarly reducing abdominal fat in NON-HIV-Infected individuals.